GeoVax to Present at Key September Investor Conferences
TL;DR
GeoVax Chairman and CEO, David Dodd, to speak at 26th Annual Global Investment Conference and Emerging Growth Conference, providing insight and potential investment opportunities.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines for infectious diseases and therapies for solid tumor cancers, with a lead clinical program in COVID-19 vaccine development.
GeoVax's clinical trials and product candidates aim to address infectious diseases and solid tumor cancers, potentially improving global health outcomes and saving lives.
GeoVax's lead clinical program, GEO-CM04S1, is being evaluated as a primary vaccine for immunocompromised patients and as a booster vaccine in patients with chronic lymphocytic leukemia.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company focused on immunotherapies and vaccines for cancers and infectious diseases, announced its participation in two upcoming investor events this September. Chairman and CEO David Dodd will present at both conferences, shedding light on the company's advancements and strategic initiatives.
The first event is the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9, 2024, at 7:00 a.m. ET at the Lotte New York Palace Hotel in New York, NY. Dodd will deliver a presentation titled “GeoVax Corporate Update,” which will be available via a webcast. Additionally, the senior management team will host one-on-one meetings with registered attendees during the conference.
The second presentation will occur at the Emerging Growth Conference on September 25, 2024, at 2:55 p.m. ET. This event will be held virtually, with a webcast of Dodd's presentation also titled “GeoVax Corporate Update.”
GeoVax is in the clinical stages of developing various vaccines and therapies, including its lead program, GEO-CM04S1, a next-generation COVID-19 vaccine. This vaccine is undergoing multiple Phase 2 clinical trials targeting different patient populations, including immunocompromised individuals and healthy patients needing a more durable booster. The company is also advancing Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, in a multicenter Phase 1/2 trial for advanced head and neck cancers.
These presentations are significant as they provide GeoVax a platform to communicate its progress and future plans to potential investors and stakeholders. The updates will likely influence investor perception and interest, given the company's strategic direction and ongoing clinical trials.
Curated from NewMediaWire
